Total dose iron dextran infusion versus oral iron for treating iron deficiency anemia in pregnant women: a randomized controlled trial.
J Matern Fetal Neonatal Med
; 32(3): 398-403, 2019 Feb.
Article
em En
| MEDLINE
| ID: mdl-28901214
ABSTRACT
STUDY OBJECTIVE:
To test safety, efficacy, and cost-effectiveness of total dose infusion (TDI) of low molecular weight (LMW) iron dextran for treatment of iron deficiency anemia (IDA) during pregnancy in comparison to oral ferrous fumarate.DESIGN:
Prospective interventional randomized controlled trial (RCT). Design classification. Canadian Task Force II3.SETTING:
Antenatal clinic and causality unit of a tertiary care referral facility and University Hospital. PATIENTS A total 66 anemic pregnant women (hemoglobin level between 7-10 g/dl). INTERVENTION Administration of a LMW iron dextran as a TDI (group A) or Oral iron ferrous fumarate 60 mg elemental iron three times daily (group B) followed by remeasurement of hemoglobin after 4 weeks. MEASURES AND MAINRESULTS:
The main outcome measure was clinical and laboratory improvement of anemia after 4 weeks of starting the therapy. Both groups showed a significant clinical improvement of anemia 4 weeks post-therapy. However, the first improvement of symptoms was significantly faster in group A. Complete blood count (CBC) as well as all iron indices were improved in both groups after 4 weeks of therapy, but were significantly better in group A than B. Side effects in group B were mainly gastrointestinal (GIT) while one case of mild hypersensitivity to TDI and another one case of local reaction at the site of injection were reported in group A.CONCLUSIONS:
It is concluded that despite being equally effective in improving both clinical and laboratory evidence of IDA, TDI allows iron restoration with a single dose faster than oral iron therapy with a reasonable safety profile. It is a good example of office one-stop therapy. Nevertheless, noninvasive selfusage at home is a clear advantage of the cheaper oral iron therapy which makes it the first choice for treating IDA in the second and third trimesters of pregnancy in tolerable cases.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Agentes_cancerigenos
Base de dados:
MEDLINE
Assunto principal:
Complicações Hematológicas na Gravidez
/
Anemia Ferropriva
/
Ferro
/
Complexo Ferro-Dextran
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
J Matern Fetal Neonatal Med
Assunto da revista:
OBSTETRICIA
/
PERINATOLOGIA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Egito